{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:02:31Z","timestamp":1771261351155,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:p>\n                    Nausea is common in migraines and is one of the most prevalent neurological disorders. Although migraine prophylaxis is known to reduce nausea, the impact of nausea treatment on migraine headache frequency remains unclear. DA-9701, a prokinetic derived from\n                    <jats:italic toggle=\"yes\">Corydalis tuber<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Pharbitidis semen<\/jats:italic>\n                    , offers serotonin 5-HT1A\/5-HT4 agonism and D2 antagonism, with a reduced risk of adverse effects associated with traditional D2 antagonists. This study assessed the efficacy and short-term tolerability of DA-9701 in treating nausea and migraine and evaluated its secondary effect on reducing the frequency of migraine headaches. A cohort of 110 migraineurs with nausea received DA-9701 for 1 month. Using a headache diary, the monthly frequency of headache and nausea was recorded during a 1-month baseline and a 1-month treatment period. Changes in the number of nausea days per month were measured as the primary outcome. Changes in headache days and days requiring acute rescue medication were assessed as secondary outcomes using the DIEPSS. Further analyses were performed according to the migraine subtypes EM and CM. Nausea days decreased by 53.7% (\u22124.65 days; 95% confidence interval (CI)\u2005\u221210.66 to\u2005\u22124.66 days;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001). Headache days were reduced by 52.2% (\u22128.18 days; 95% CI\u2005\u221215.35 to\u2005\u221211.19 days;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001), and rescue medication days by 44.8% (\u22123.46 days; 95% CI\u2005\u22126.75 to\u2005\u22121.00 days;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001). In the CM group, changes in headache days were more prominent than those in nausea days (\u221213.47 vs \u22127.12 days;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001). No EPS or other clinically relevant adverse events were observed. DA-9701 was well tolerated and reduced both nausea and headache in migraineurs. The CM data suggest a potential independent prophylactic effect of DA-9701 on migraine headache. Larger randomized controlled trials are warranted.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047623","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:00:54Z","timestamp":1771005654000},"page":"e47623","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A prokinetic agent DA-9701 formulated with Corydalis tuber and Pharbitidis semen improves nausea in migraine: A prospective observational study"],"prefix":"10.1097","volume":"105","author":[{"given":"Hyoshin","family":"Son","sequence":"first","affiliation":[{"name":"Department of Neurology, Eunpyeong St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seunghyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical School, Jeonbuk National University, Jeonju, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Ji","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, Seoul National University Hospital, Seoul, Korea"},{"name":"Department of Neurology, Seoul National University College of Medicine, Seoul, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-6326","authenticated-orcid":false,"given":"Manho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Seoul National University Hospital, Seoul, Korea"},{"name":"Department of Neurology, Seoul National University College of Medicine, Seoul, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260216","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy.","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"key":"R2-20260216","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1046\/j.1526-4610.1998.3805356.x","article-title":"Epidemiologic and clinical characteristics of migraine and tension-type headache in Korea.","volume":"38","author":"Roh","year":"1998","journal-title":"Headache"},{"key":"R3-20260216","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/head.12482","article-title":"The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies.","volume":"55","author":"Burch","year":"2015","journal-title":"Headache"},{"key":"R4-20260216","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1526-4610.2001.041007646.x","article-title":"Prevalence and burden of migraine in the United States: data from the American Migraine Study II.","volume":"41","author":"Lipton","year":"2001","journal-title":"Headache"},{"key":"R5-20260216","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1177\/0333102419857596","article-title":"Prevalence and pathophysiology of post-prandial migraine in patients with functional dyspepsia.","volume":"39","author":"Di Stefano","year":"2019","journal-title":"Cephalalgia"},{"key":"R6-20260216","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-230X-6-26","article-title":"Migraine, fibromyalgia, and depression among people with IBS: a prevalence study.","volume":"6","author":"Cole","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"R7-20260216","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/0333102411401635","article-title":"Migraine features, associated symptoms and triggers: a principal component analysis in the Women\u2019s Health Study.","volume":"31","author":"Schurks","year":"2011","journal-title":"Cephalalgia"},{"key":"R8-20260216","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11916-013-0362-7","article-title":"Why does vomiting stop a migraine attack?","volume":"17","author":"Chai","year":"2013","journal-title":"Curr Pain Headache Rep"},{"key":"R9-20260216","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ajem.2014.11.013","article-title":"Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis.","volume":"33","author":"Eken","year":"2015","journal-title":"Am J Emerg Med"},{"key":"R10-20260216","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"Ashina","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-20260216","first-page":"e1181","article-title":"Metoclopramide for acute migraine treatment in the emergency department: an effective alternative to opioids.","volume":"9","author":"Najjar","year":"2017","journal-title":"Cureus"},{"key":"R12-20260216","doi-asserted-by":"crossref","first-page":"650718","DOI":"10.1155\/2012\/650718","article-title":"Effect of a new prokinetic agent DA-9701 formulated with Corydalis tuber and Pharbitidis semen on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes.","volume":"2012","author":"Ji","year":"2012","journal-title":"Evid Based Complement Alternat Med"},{"key":"R13-20260216","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4062\/biomolther.2012.096","article-title":"DA-9701: A new multi-acting drug for the treatment of functional dyspepsia.","volume":"21","author":"Kwon","year":"2013","journal-title":"Biomol Ther (Seoul)"},{"key":"R14-20260216","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15299\/jk.2016.5.59.41","article-title":"Efficacy and safety of motilitone in migraine patients with gastrointestinal symptoms.","volume":"17","author":"Kim","year":"2016","journal-title":"Korean J Headache"},{"key":"R15-20260216","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5056\/jnm14019","article-title":"Effects of the new prokinetic agent DA-9701 formulated with Corydalis tuber and Pharbitis seed in patients with minimal change esophagitis: a bicenter, randomized, double blind, placebo-controlled study.","volume":"20","author":"Park","year":"2014","journal-title":"J Neurogastroenterol Motil"},{"key":"R16-20260216","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5056\/jnm20236","article-title":"A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of DA-9701 (Motilitone) in patients with constipation-type irritable bowel syndrome and functional dyspepsia overlap: a pilot study.","volume":"28","author":"Lee","year":"2022","journal-title":"J Neurogastroenterol Motil"},{"key":"R17-20260216","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","article-title":"Chronic migraine: risk factors, mechanisms and treatment.","volume":"12","author":"May","year":"2016","journal-title":"Nat Rev Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:02:24Z","timestamp":1771257744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047623","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2024-03-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}